Luis Lopez-Guerra, Jose , VERDUGO SIVIANES, EVA MARÍA, Otero-Albiol, Daniel , Vieites, Begona , Ortiz-Gordillo, Maria J. , De Leon, Jose M. , Praena-Fernandez, Juan M. , Marin, Juan J. , Carnero, Amancio
No
Oncotarget
Article
Científica
5.008
2.26
06/10/2015
000363183200142
Reliable biological markers that predict breast cancer (BC) outcomes after multidisciplinary therapy have not been fully elucidated. We investigated the association between casein kinase 1 epsilon (CK1 epsilon) and the risk of recurrence in patients with BC. Using 168 available tumor samples from patients with BC treated with surgery +/-chemo(radio) therapy, we scored the CK1 epsilon expression as high (>= 1.5) or low (<1.5) using an immunohistochemical method. Kaplan-Meier analysis was performed to assess the risk of relapse, and Cox proportional hazards analyses were utilized to evaluate the effect of CK1 epsilon expression on this risk. The median age at diagnosis was 60 years (range 35-96). A total of 58% of the patients underwent breast conservation surgery, while 42% underwent mastectomy. Adjuvant chemotherapy and radiation therapy were administered in 101 (60%) and 137 cases (82%), respectively. Relapse was observed in 24 patients (14%). Multivariate analysis found high expression of CK1 epsilon to be associated with a statistically significant higher disease-free survival (DFS) in BC patients with wild-type p53 (Hazard ratio [HR] = 0.33; 95% CI, 0.12-0.91; P = 0.018) or poor histological differentiation ([HR] = 0.34; 95% CI, 0.12-0.94; P = 0.039) or in those without adjuvant chemotherapy ([HR] = 0.11; 95% CI, 0.01-0.97; P = 0.006). Our data indicate that CK1 epsilon expression is associated with DFS in BC patients with wild-type p53 or poor histological differentiation or in those without adjuvant chemotherapy and thus may serve as a predictor of recurrence in these subsets of patients.
breast cancer; casein kinase 1 epsilon (CK1 epsilon); relapse; disease-free survival; outcome